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Abstract
The ataxia telangiectasia mutated (ATM) and the ATM- related (ATR) kinases play a central role in
facilitating the resistance of cancer cells to genotoxic treatment regimens. The components of the
ATM and ATR regulated signaling pathways thus provide attractive pharmacological targets, since
their inhibition enhances cellular sensitivity to chemo- and radiotherapy. Caffeine as well as more
specific inhibitors of ATM (KU55933) or ATM and ATR (CGK733) have recently been shown to
induce cell death in drug-induced senescent tumor cells. Addition of these agents to cancer cells
previously rendered senescent by exposure to genotoxins suppressed the ATM mediated p21
expression required for the survival of these cells. The precise molecular pharmacology of these
agents however, is not well characterized. Herein, we report that caffeine, CGK733, and to a lesser
extent KU55933, inhibit the proliferation of otherwise untreated human cancer and non-
transformed mouse fibroblast cell lines. Exposure of human cancer cell lines to caffeine and
CGK733 was associated with a rapid decline in cyclin D1 protein levels and a reduction in the levels
of both phosphorylated and total retinoblastoma protein (RB). Our studies suggest that
observations based on the effects of these compounds on cell proliferation and survival must be
interpreted with caution. The differential effects of caffeine/CGK733 and KU55933 on cyclin D1
protein levels suggest that these agents will exhibit dissimilar molecular pharmacological profiles.
Background
ATM and ATR cooperate to mediate cellular responses to
DNA damage, following exposure to diverse genotoxic
agents. These include induction of cell cycle arrest, DNA
repair, maintenance of genomic stability, induction of
premature senescence and cell death [1-3]. The coordi-
nated activation of these processes has been defined as the
DNA damage response pathway (DDR). Initial studies
demonstrated that inhibition of ATM and ATR by caffeine
significantly enhanced cellular sensitivity to ionizing radi-
ation (IR) [4]. Inhibiting ATM, ATR or their downstream
targets thus serves to widen the therapeutic window of
genotoxic anti-cancer therapeutics by sensitizing cancer
cells to these agents (reviewed [5]). The relative non-spe-
cificity of caffeine has lead to the search for more specific
inhibitors of ATM and ATR. The small molecule inhibitor
2-morpholin-4-yl-6-thianthren-1-yl-pyran-4-one
(KU55933) has been shown to specifically inhibit ATM in
the low nanomolar range (IC50:12.9 nM). In contrast,
KU55933 did not inhibit ATR at doses of up to 100 μM
[6]. KU55933 has been shown to sensitize cancer cells to
both IR and chemotherapeutic agents [6,7]. CGK733, a
thiourea-containing compound, was originally identified
as an inhibitor of ATM and ATR with an IC50 of ~200 nM
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towards both kinases [8]. This study was subsequently
retracted, leaving the precise molecular pharmacology of
this compound unclear. Additional studies suggest how-
ever, that CGK733 inhibits ATM and ATR [9-12]. More
recently, caffeine, CGK733 and KU55933 have been
shown to induce cell death in prematurely senescent
breast cancer cells [13]. The induction of premature senes-
cence by genotoxic agents contributes to drug sensitivity
and is primarily (but not solely) dependent on p53-
induced p21 expression [14,15]. Cancer cells that have
undergone drug-induced premature senescence are less
sensitive to pro-apoptotic signaling and can re-enter the
cell cycle [16-20]. The study by Crescenzi et al. [13] sug-
gests that ATM is required for the maintenance of the pre-
mature senescent phenotype and hence the survival of
cancer cells exposed to genotoxins. Combining ATM and/
or ATR inhibitors with genotoxins may thus further
enhance the cytotoxicity of these agents, by preventing
drug induced senescence as a therapeutic outcome [13].
The molecular pharmacology of inhibitors like CGK733
and KU55933 will require further characterization. ATR
unlike ATM regulates cell cycle progression in the absence
of DNA damage and is required for the viability of prolif-
erating human and mouse cells [1]. Inhibitors that target
both ATM and ATR are thus likely to exhibit pharmacolog-
ical profiles that are distinct from ATM selective inhibi-
tors. It is also likely, that the genetic make up of a
particular subset of cancer cells influences their relative
sensitivity to ATM and/or ATR inhibitors [21,22].
Methods
Reagents
Stock solutions of caffeine (100 mM in water) (Sigma
Aldrich, Stockholm, Sweden), CGK733 (20 mM) and
KU55933 (10 mM) (Calbiochem, VWR International AB,
Stockholm, Sweden) dissolved in dimethyl sulphoxide
(DMSO) were stored at -20°C. Lithium Chloride (40
mM) (Sigma-Aldrich) was dissolved in sterile distilled
water and stored at 4°C. The proteasome inhibitor
MG132 (50 mM) (Sigma- Aldrich) was dissolved in
DMSO and stored at -20°C. Caspase inhibitor I (40 mM)
(Z-VAD (OMe)-FMK (Calbiochem) was dissolved in
DMSO and stored at -20°C. Monoclonal antibodies
raised against cyclin D1 (DCS-6) (Santa Cruz Biotechnol-
ogy, Santa Cruz, CA), RB (G3-245) (Becton Dickinson AB,
Stockholm, Sweden), α- Tubulin (Sigma- Aldrich), and
Hsp60 (Abcam, Cambridge, United Kingdom) were used.
Cell culture
LNCaP, MCF-7, MDA-MB436 and T47D cells were cul-
tured in RPMI 1640 supplemented with 10% (v/v) fetal
calf serum, 2 mM L-glutamine, 100 units/ml penicillin
and 100 μg/ml streptomycin at 37°C in humidified 5%
CO2. HCT116 and BALB/c 3T3 cells were cultured in Dul-
becco's modified eagle medium (DMEM) supplemented
with 10% (v/v) fetal calf serum, 2 mM L-glutamine, 100
units/ml penicillin and 100 μg/ml streptomycin at 37°C
in humidified 5% CO2.
Cell proliferation assay
Cells were seeded in 96-well plates at a predetermined
optimal cell density to ensure exponential growth for
duration of the assay. After a 24 h preincubation, growth
medium was replaced with experimental medium con-
taining the appropriate drug concentrations or 0.1% (v/v)
vehicle control. After a 48 h incubation, cell proliferation
was estimated using the sulforhodamine B colorimetric
assay [23] and expressed as the mean ± SE for six replicates
as a percentage of vehicle control (taken as 100%). Exper-
iments were performed independently at least three times.
Statistical analyses were performed using a two-tailed Stu-
dent's t test. P < 0.05 was considered to be statistically sig-
nificant.
Immunoblotting
Cells treated as indicated were harvested in 5 ml of
medium, pelleted by centrifugation (1,600 rpm for 5 min
at 4°C), washed twice with ice-cold phosphate buffered
saline (PBS) and lysed in ice-cold HEPES buffer [50 mM
HEPES (pH 7.5), 10 mM NaCl, 5 mM MgCl2, 1 mM EDTA,
10% (v/v) glycerol, 1% (v/v) Triton X-100 and a cocktail
of protease inhibitors (Roche Diagnostics Scandinavia AB,
Bromma, Sweden)] on ice for 30 min. Lysates were clari-
fied by centrifugation (13,000 rpm for 15 min at 4°C)
and the supernatants then either analyzed immediately or
stored at -80°C. Equivalent amounts of protein (20 - 50
μg) from total cell lysates were resolved by SDS-PAGE and
transferred onto 'nitrocellulose membranes. Membranes
were blocked in blocking buffer [5% (w/v) nonfat dried
milk, 150 mM NaCl, 10 mM Tris (pH 8.0) and 0.05% (v/
v) Tween 20]. Proteins were detected by incubation with
primary antibodies at appropriate dilutions in blocking
buffer overnight at 4°C. Blots were then incubated at
room temperature with horseradish peroxidase-conju-
gated secondary antibody. Bands were visualized by
enhanced chemiluminescence (Supersignal West Pico;
Pierce, Nordic Biolabs AB, Täby, Sweden) followed by
exposure to autoradiography film (General Electric Bio-
Sciences, Uppsala, Sweden).
Immunofluorescence microscopy
MCF-7 cells were grown on sterile glass coverslips in 6-
well plates to 80% confluence in media before being
washed three times in PBS. Cells were fixed in 4% formal-
dehyde/PBS at room temperature for 10 minutes. Cover-
slips were washed twice in PBS and permeabilized in 0.2%
Triton X100/PBS for 15 minutes. Following another three
washes in PBS, coverslips were blocked in 3% bovine
serum albumen (BSA)/PBS at room temperature for 30
min. Antibodies to Cyclin D1 (DCS-6) (Santa Cruz) (1:50Radiation Oncology 2009, 4:51 http://www.ro-journal.com/content/4/1/51
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dilution) were applied in 3% BSA/PBS medium overnight.
Cells were washed then washed 3 times in PBS, and incu-
bated with a rhodamine (TRITC)- conjugated goat anti-
mouse secondary antibody (1:200) (Jackson Immunore-
search, Fisher Scientific AB, Gothenburg, Sweden) at
room temperature for 1 h. After a final 3 washes, cover-
slips were mounted on glass slides with Vectorshield con-
taining 4', 6'-diamidino-2-phenylindole(DAPI) (Vector
Laboratories Ltd., Peterborough, United Kingdom).
Images were obtained with a Zeiss AxioCam on a Zeiss
Axioplan 2 microscope with a 100 × objective using the
appropriate filter sets.
Results
In this work, we observe that CGK733 induces the loss of
cyclin D1 via the ubiquitin- dependent proteasomal deg-
radation pathway in MCF-7 and T47D breast cancer cell
lines. Culture of MCF-7 breast cancer cells with 10 μM
CGK733 induced a detectable decline of cyclin D1 levels
within 2 h of exposure, and this effect was maximal
between 4 and 6 h after exposure (Figure 1A). CGK733
induced the loss of cyclin D1 expression at concentrations
as low as 5 μM and this activity was maximal at 10 to 20
μM (Figure 1B). CGK733 similarly induced loss of cyclin
D1 protein in T47D cells at these concentrations (Figure
1C). The phosphorylation of cyclin D1 residue threonine
286 (T286) by GSK3β greatly enhances its degradation by
the ubiquitin- 26S proteasome pathway. Several agents
that induce cyclin D1 ablation have been shown to do so
in a GSK3β dependent manner [24]. The CGK733
induced attenuation of cyclin D1 levels was inhibited by
the 26S proteasome inhibitor MG132 but not the GSK3β
inhibitor lithium chloride (LiCl) in MCF-7 and T47D cells
(Figure 1D and 1E). CGK733 thus induces the loss of cyc-
lin D1 protein via the ubiquitin- 26S proteasome pathway
independently of GSK3β mediated T286 phosphoryla-
tion. GSK3β regulates cyclin D1 stability by facilitating its
CRM1-dependent nuclear export and subsequent degra-
dation within the cytoplasm [25,26]. Accordingly,
CGK733 did not affect the subcellular localization of cyc-
lin D1 (Figure 1F). CGK733 also induced ubiquitin-
dependent loss of cyclin D1 in LNCaP prostate cancer cells
(Figure 1G), indicating that this effect is not breast cancer
specific. We also observed that caffeine induced the ubiq-
uitin- dependent loss of cyclin D1 in MCF-7 cells (Figure
1H). In contrast, KU55933 did not affect cyclin D1 stabil-
ity at the commonly used concentration of 10 μM for up
to 24 h after exposure (Figure 1I). Cyclin D1 forms active
kinase complexes with cyclin dependent kinase 4 (CDK4)
or CDK6 that phosphorylate and hence inactivate the
retinoblastoma tumor suppressor protein (RB) (reviewed
in [27]). Caffeine and CGK733 but not KU55933 induced
a significant decline in the levels of both phosphorylated
and total RB protein levels in MCF-7 cells (Figure 1I and
1J).
Cyclin D1 activity is required for G1- S phase progression
and the regulation of its expression and/or stability is
often deregulated in cancer cells (reviewed in [24]). Previ-
ously, we demonstrated that cyclin D1 is essential for the
proliferation of MCF-7 cancer cells [28]. We thus investi-
gated the effect of caffeine, CGK733 and KU55933 on the
proliferation of a panel of human cancer cell lines derived
from solid tumors. Various studies have used CGK733 at
concentrations ranging from 0.6- 40 μM (Table 1). In our
study, CGK733 inhibited proliferation of MCF-7 and
T47D estrogen receptor (ER) positive breast cancer cells,
MDA-MB436 ER negative breast cancer cells, LnCap pros-
tate cancer cells and HCT116 colon cancer cells (Figure
2A). Furthermore, CGK733 also suppressed proliferation
of non- transformed mouse BALB/c 3T3 embryonic
fibroblast cells (Figure 2A). The CGK733-mediated inhi-
bition of proliferation was dose dependent and significant
at doses as low as 2.5 μM. Culture of MCF-7 and T47D
cells with 5 mM caffeine inhibited cell proliferation to a
similar degree as CGK733 (Figure 2B). KU55933 maxi-
mally inhibits cellular ATM kinase activity at 10 μM and
was originally reported not to inhibit cell proliferation at
this concentration [6]. KU55933 has been used at doses
ranging from 1 to 40 μM (Table 1), and later studies sug-
gested that some cell lines exhibit sensitivity to this inhib-
itor at concentrations between 10 and 20 μM [21]. We
observed that KU55933 inhibited proliferation of MCF-7
and T47D cells at concentrations ranging from 10 to 30
μM (Figure 2B and 2C). The ability of caffeine and
CGK733 to induce the loss of cyclin D1 expression is thus
likely to enhance their anti-proliferative activity at high
concentrations.
Crescenzi et al [13] recently reported that caffeine (1- 5
mM), CGK733 (10 - 20 μM) and KU55933 (20 - 40 μM)
induced senescent cancer cells to undergo caspase-
dependent apoptosis. Our findings demonstrate, how-
ever, that these compounds inhibit the proliferation of
otherwise untreated cancer and non- transformed cell
lines (Figure 2). In contrast to that study however, pan-
caspase inhibition did not suppress the anti-proliferative
effect of CGK733 on MCF-7 cells in our experiments (Fig-
ure 3A). Although the nuclei of CGK733 treated cells
appeared condensed, we did not detect the nuclear frag-
mentation normally detected in apoptotic MCF-7 cells
(Figure 3B) [13]. Caffeine, CGK733 and KU55933 may
thus suppress proliferation of senescent and non- senes-
cent cancer cells via different mechanisms.
Discussion
Small molecule selective inhibitors of ATM and/or ATR
provide powerful tools for studies on the cellular func-
tions of these kinases. Furthermore, these molecules may
eventually be used alongside regular anti-cancer agents as
chemo- and radiosensitizers (reviewed in [5]). In thisRadiation Oncology 2009, 4:51 http://www.ro-journal.com/content/4/1/51
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Figure 1
Effect of CGK733, caffeine and KU55933 on cyclin D1 stability. A. MCF-7 breast cancer cells were cultured with 10
μM CGK733 for the indicated times. Total lysates were resolved by SDS- PAGE and analyzed for cyclin D1 expression. Gel
loading was monitored with an antibody raised against Hsp60. B. MCF-7 cells were cultured with the indicated concentrations
of CGK733 for 6 h and analyzed as in A. C. T47D breast cancer cells were treated as in B. D. MCF-7 cells were incubated with
10 μM CGK733 alone or in the presence of 40 mM LiCl or 25 μM MG132 for 6 h and analyzed for cyclin D1 expression. Gel
loading was monitored with an antibody directed against α- Tubulin. E. T47D cells were treated as in D. F. MCF-7 cells were
grown on coverslips and treated with 10 μM CGK733 ± 25 μM MG132 for 6 h. Cyclin D1 expression was determined by indi-
rect immunofluorescence microscopy as described in Materials and methods. Scale bar 10 μm. G. LnCap prostate cancer cells
were treated and analyzed as in D. H. MCF-7 cells were cultured with 5 mM caffeine ± 25 μM MG132 for 6 h and analyzed as
in D. I. MCF-7 cells were cultured in the presence of 5 mM caffeine, 10 μM CGK733 or 20 μM KU55933 for 24 h and analyzed
for RB and cyclin D1 expression. J. MCF-7 cells were cultured with the indicated concentrations of CGK733 for 24 h and ana-
lyzed as in I.Radiation Oncology 2009, 4:51 http://www.ro-journal.com/content/4/1/51
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Effect of CGK733, caffeine and KU55933 on cell proliferation Figure 2
Effect of CGK733, caffeine and KU55933 on cell proliferation. A. MCF-7, T47D and MDA-MB436 breast cancer cells, 
LNCaP prostate cancer cells, HCT116 colon cancer cells and BALB/c 3T3 fibroblasts were cultured with the indicated doses of 
CGK733 for 48 h. Cell proliferation was measured as described in Materials and methods. Results represent the mean ± S.E. 
from three independent experiments. *, P < 0.05, compared with control; **, P < 0.005, compared with control. B. MCF-7 cells 
were cultured with the indicated doses of caffeine, CGK733 and KU55933 for 48 h. Cell proliferation was monitored as in A. 
Results represent the mean ± S.E. from three independent experiments. **, P < 0.005, compared with control. C. T47D cells 
were cultured with the indicated doses of caffeine, CGK733 and KU55933 for 48 h. Cell proliferation was monitored as in A. 
Results represent the mean ± S.E. from three independent experiments. *, P < 0.05, compared with control; **, P < 0.005, 
compared with control.
Table 1: Inhibitors of ATM and/or ATR
Study Inhibitor/Concentration Reference
Caffeine CGK733 KU55933
Hickson et al., 2004 -- 0.03- 10 μM[ 6]
Cowell et al., 2005 - - 1-20 μM[ 7]
Byrant and Helleday, 2006 - - 2-20 μM[ 21]
Nakai-Murakami et al., 2007 - - 1 mM [32]
Al-Minawi et al., 2008 2 mM 10 μM- [ 33]
Yamauchi et al., 2008 - - 10 μM[ 34]
Cruet-Hennequart et al., 2008 - 10 μM1 0   μM[ 10]
Goldstein et al., 2008 - 0.6 μM- [ 11]
Crescenzi et al., 2008 1-5 mM 10- 20 μM 20- 40 μM[ 13]
Bhattacharya et al., 2008 - 20 μM- [ 9]
Selected studies involving the exposure of mammalian cell lines to the ATM and/or ATR inhibitors caffeine, CGK733 and KU55933.Radiation Oncology 2009, 4:51 http://www.ro-journal.com/content/4/1/51
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study, we have observed that in contrast to the ATM selec-
tive inhibitor KU55933, ATM/ATR dual inhibitors such as
caffeine and CGK733 can suppress cyclin D1 levels in can-
cer cell lines. A recent study suggests that mitogen-acti-
vated cyclin D1 expression is required for the induction of
premature senescence [29]. Interestingly, cyclin D1
expression is elevated in cells that have been induced to
undergo premature senescence [30]. The function of cyc-
lin D1 in this non-dividing cell population has not been
determined. Our findings show that single and dual ATM/
ATR kinase inhibitors are not interchangeable and may
thus differentially influence cell fate in a cell type and con-
text dependent manner. KU55933 has been shown to
enhance the radiosensitivity of cancer cells [6] but the
impact of senescence suppression on this sensitizing effect
remains unclear. Future studies will address how the
effect(s) of caffeine and CGK733 on cyclin D1 expression,
in turn impact on their chemo- and radiosensitizing prop-
erties. It remains unclear if the decline in cyclin D1 levels
results from ATR inhibition, the inhibition of both ATM
and ATR, or from the inhibition of an unknown target. It
should be noted however, that the siRNA-mediated
knockdown of ATR induced cyclin D1 accumulation in
NIH 3T3 cells [31]. It is also conceivable, that the antipro-
liferative effects of ATM/ATR inhibitors observed at high
does may result from off- target effects. It remains to be
determined, if these agents exert cytotoxic effects on senes-
cent cancer cells at lower doses [13]. Observations on can-
cer cell proliferation and survival based on the use of
ATM/ATR inhibitors should thus be interpreted with cau-
tion.
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